Inhibition of SARS-CoV-2 Infection by and the Oral Microbiome

Overview

Journal Microbiol Spectr

Specialty Microbiology

Date 2024 Aug 20

PMID 39162507

Authors

Alexander Bontempo

Alexandra Chirino

Alireza Heidari

Alexandra Lugo

Satoru Shindo

Maria R Pastore

Riccardo Madonia

Sibel A Antonson

Cristina Godoy

Frank C Nichols

Jan Potempa

Mary Ellen Davey

Toshihisa Kawai

Mark J Cayabyab

Affiliations

Soon will be listed here.

Abstract

Importance: The oral microbiome is important in health and disease, and in this study, we addressed the potential role of the oral microbiome in COVID-19 infection. Our studies suggest that certain bacteria of the oral microbiome such as produce compounds that could potentially inhibit SARS-CoV-2 infection. These findings elucidating the interactions between the oral microbiome and SARS-CoV-2 infection will be important in our understanding of COVID-19 pathogenesis and the development of innovative therapeutic and preventive strategies against COVID-19 infection.

Citing Articles

Using In Vitro Models to Study the Interactions Between Environmental Exposures and Human Microbiota.

Cheng Q, Chen S Microorganisms. 2025; 13(2).

PMID: 40005610 PMC: 11857843. DOI: 10.3390/microorganisms13020247.

References

Li N, Ma W, Pang M, Fan Q, Hua J . The Commensal Microbiota and Viral Infection: A Comprehensive Review. Front Immunol. 2019; 10:1551. PMC: 6620863. DOI: 10.3389/fimmu.2019.01551. View

Veillard F, Potempa B, Poreba M, Drag M, Potempa J . Gingipain aminopeptidase activities in Porphyromonas gingivalis. Biol Chem. 2013; 393(12):1471-6. PMC: 4180661. DOI: 10.1515/hsz-2012-0222. View

Dzimianski J, Lorig-Roach N, ORourke S, Alexander D, Kimmey J, DuBois R . Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry. Sci Rep. 2020; 10(1):21738. PMC: 7730435. DOI: 10.1038/s41598-020-78895-x. View

Moreno C, Boeree E, Tellez Freitas C, Weber K . Immunomodulatory role of oral microbiota in inflammatory diseases and allergic conditions. Front Allergy. 2023; 4:1067483. PMC: 9981797. DOI: 10.3389/falgy.2023.1067483. View

McGowan V, Bambra C . COVID-19 mortality and deprivation: pandemic, syndemic, and endemic health inequalities. Lancet Public Health. 2022; 7(11):e966-e975. PMC: 9629845. DOI: 10.1016/S2468-2667(22)00223-7. View

Bao L, Zhang C, Dong J, Zhao L, Li Y, Sun J . Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection. Front Microbiol. 2020; 11:1840. PMC: 7411080. DOI: 10.3389/fmicb.2020.01840. View

Henderson B, Ward J, Ready D . Aggregatibacter (Actinobacillus) actinomycetemcomitans: a triple A* periodontopathogen?. Periodontol 2000. 2010; 54(1):78-105. DOI: 10.1111/j.1600-0757.2009.00331.x. View

Shreiner A, Kao J, Young V . The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2014; 31(1):69-75. PMC: 4290017. DOI: 10.1097/MOG.0000000000000139. View

Marouf N, Cai W, Said K, Daas H, Diab H, Chinta V . Association between periodontitis and severity of COVID-19 infection: A case-control study. J Clin Periodontol. 2021; 48(4):483-491. PMC: 8014679. DOI: 10.1111/jcpe.13435. View

10.

Nichols F, Clark R, Liu Y, Provatas A, Dietz C, Zhu Q . Glycine Lipids of Porphyromonas gingivalis Are Agonists for Toll-Like Receptor 2. Infect Immun. 2020; 88(4). PMC: 7093120. DOI: 10.1128/IAI.00877-19. View

11.

Yeoh Y, Zuo T, Lui G, Zhang F, Liu Q, Li A . Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021; 70(4):698-706. PMC: 7804842. DOI: 10.1136/gutjnl-2020-323020. View

12.

Chaisuwan W, Phimolsiripol Y, Chaiyaso T, Techapun C, Leksawasdi N, Jantanasakulwong K . The Antiviral Activity of Bacterial, Fungal, and Algal Polysaccharides as Bioactive Ingredients: Potential Uses for Enhancing Immune Systems and Preventing Viruses. Front Nutr. 2021; 8:772033. PMC: 8602887. DOI: 10.3389/fnut.2021.772033. View

13.

BLIGH E, Dyer W . A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8):911-7. DOI: 10.1139/o59-099. View

14.

Moradi Haghgoo J, Torkzaban P, Farhadian M, Moosavi Sedeh S . Association between the severity of periodontitis, COVID-19, C-reactive protein and interleukin-6 levels in hospitalized patients: a case‒control study. BMC Oral Health. 2023; 23(1):556. PMC: 10422752. DOI: 10.1186/s12903-023-03270-x. View

15.

Zhong M, Lin B, Pathak J, Gao H, Young A, Wang X . ACE2 and Furin Expressions in Oral Epithelial Cells Possibly Facilitate COVID-19 Infection via Respiratory and Fecal-Oral Routes. Front Med (Lausanne). 2020; 7:580796. PMC: 7758442. DOI: 10.3389/fmed.2020.580796. View

16.

Socransky S, Haffajee A, Cugini M, Smith C, Kent Jr R . Microbial complexes in subgingival plaque. J Clin Periodontol. 1998; 25(2):134-44. DOI: 10.1111/j.1600-051x.1998.tb02419.x. View

17.

Raihan T, Rabbee M, Roy P, Choudhury S, Baek K, Azad A . Microbial Metabolites: The Emerging Hotspot of Antiviral Compounds as Potential Candidates to Avert Viral Pandemic Alike COVID-19. Front Mol Biosci. 2021; 8:732256. PMC: 8452873. DOI: 10.3389/fmolb.2021.732256. View

18.

Pyrc K, Strzyz P, Milewska A, Golda A, Schildgen O, Potempa J . Porphyromonas gingivalis enzymes enhance infection with human metapneumovirus in vitro. J Gen Virol. 2011; 92(Pt 10):2324-2332. DOI: 10.1099/vir.0.032094-0. View

19.

Shah H, Gharbia S, OToole C . Assessment of the relative cytotoxicity of Porphyromonas gingivalis cells, products, and components on human epithelial cell lines. J Periodontol. 1992; 63(1):44-51. DOI: 10.1902/jop.1992.63.1.44. View

20.

Griffen A, Becker M, Lyons S, Moeschberger M, Leys E . Prevalence of Porphyromonas gingivalis and periodontal health status. J Clin Microbiol. 1998; 36(11):3239-42. PMC: 105308. DOI: 10.1128/JCM.36.11.3239-3242.1998. View